PhaseBio To Report Third Quarter 2019 Financial Results and Recent Corporate Progress on November 14, 2019
MALVERN, Pa. and SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that on November 14, 2019, before the open of the U.S. financial markets, it will report financial results for the third quarter 2019 and recent corporate progress.
For more information on PhaseBio and to receive PhaseBio’s press releases, please visit the Investors section of the company’s website at and register for email alerts.
About PhaseBio
is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-like polypeptide (“ELP”) technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio’s second product candidate PB1046, which is based on ELP, is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension.
PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit .
Investor Contact:
John Sharp
PhaseBio Pharmaceuticals, Inc.
Chief Financial Officer
(610) 981-6506
Media Contact:
Gina Cestari
6 Degrees
(917) 797-7904
